Kintara: Topline Results From Adjuvant Arm Affirms Efficacy Of VAL-083

(RTTNews) - Kintara Therapeutics, Inc. (KTRA) reported topline data results from adjuvant arm of phase 2 study of VAL-083 in newly-diagnosed glioblastoma multiforme patients. The company said the topline results further affirmed the efficacy and safety data reported in July from the recurrent arm, thus providing additional support to continue the evaluation of VAL-083 for the treatment of glioblastoma multiforme.

VAL-083 has been granted Orphan Drug Designation for glioblastoma multiforme by the FDA and EMA and has also been granted Orphan Drug Designations for medulloblastoma and ovarian cancer by the FDA.

Shares of Kintara Therapeutics were up 4.5% in pre-market trade on Wednesday.